SCHEMBL19899801

SCHEMBL19899801

CCCCCCCCCCCCCCc1nc(N2CCC2)nc(N2CCC2)c1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPY5R Q15761 2/20 0.36
▸ MEN1 O00255 4/20 0.35
▸ KMT2A Q03164 4/20 0.35
▸ LMNA P02545 2/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ ALDH1A1 P00352 3/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ HTT P42858 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ PDE4A P27815 1/20 0.33
▸ PDE4B Q07343 1/20 0.33
▸ PDE4C Q08493 1/20 0.33
▸ PDE4D Q08499 1/20 0.33
▸ PDE3B Q13370 1/20 0.33
▸ PDE3A Q14432 1/20 0.33
▸ CHRM1 P11229 1/20 0.32
▸ TLR9 Q9NR96 1/20 0.32
▸ TLR7 Q9NYK1 1/20 0.32
▸ CETP P11597 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19900131 1.00 NPY5R (0.36) NPY5RMEN1KMT2ALMNASMN1; SMN2
SCHEMBL18029915 0.88 MEN1 (0.36) NPY5RMEN1KMT2ALMNASMN1; SMN2
SCHEMBL18005531 0.86 KDM4E (0.35) NPY5RMEN1KMT2ALMNASMN1; SMN2
SCHEMBL19900162 0.83 NPY5R (0.36) NPY5RMEN1KMT2ALMNASMN1; SMN2
SCHEMBL19900182 0.83 NPY5R (0.36) NPY5RMEN1KMT2ALMNASMN1; SMN2
SCHEMBL18005415 0.82 KCNQ3 (0.38) MEN1KMT2ALMNAHTTATM
SCHEMBL18005359 0.81 SMN1; SMN2 (0.35) MEN1KMT2ALMNASMN1; SMN2NPSR1
SCHEMBL22509220 0.81 SMN1; SMN2 (0.35) MEN1KMT2ALMNASMN1; SMN2NPSR1
SCHEMBL18005432 0.81 CNR1 (0.32) MEN1KMT2ALMNAKDM4ECHRM1
SCHEMBL18005358 0.77 CHRM1 (0.30) CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12595250-B2 Substituted pyrimidine compounds as multifunctional radical quenchers and their uses ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2026-04-07 — — US disclosed
US-20220324841-A1 THERAPEUTIC COMPOUNDS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2022-10-13 — — US disclosed
US-11390605-B2 Substituted pyrimidine compounds as multifunctional radical quenchers and their uses ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2022-07-19 — — US disclosed
US-20210276979-A1 THERAPEUTIC COMPOUNDS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2021-09-09 — — US disclosed
US-20210276979-A1 THERAPEUTIC COMPOUNDS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2021-09-09 — — US disclosed
WO-2018039077-A1 THERAPEUTIC COMPOUNDS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-03-01 — — WO disclosed
WO-2018039077-A1 THERAPEUTIC COMPOUNDS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-03-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12595250-B2 Substituted pyrimidine compounds as multifunctional radical quenchers and their uses GSR, UQCRC1, TXNRD2 NPY5R 720/4885MEN1 3423/4885KMT2A 4105/4885
US-20220324841-A1 THERAPEUTIC COMPOUNDS CFTR, F12, FURIN NPY5R 1478/4885MEN1 144/4885KMT2A 4374/4885
US-20210276979-A1 THERAPEUTIC COMPOUNDS CFTR, F12, FURIN NPY5R 1478/4885MEN1 144/4885KMT2A 4374/4885
US-11390605-B2 Substituted pyrimidine compounds as multifunctional radical quenchers and their uses DPYD, TYMP, NUDT1 NPY5R 2206/4885MEN1 2429/4885KMT2A 3315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback